Schizophrenia Clinical Trials in Houston, Texas

12 studies are recruiting for schizophrenia in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Circuitry-Guided Smoking Cessation in Schizophrenia (UH3)

   Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from F8 coil or active rTMS from H coil for smoking cessation. Smoking and brain functional connectivity changes will be assessed at baseline, different stages of rTMS a…

   Stage

   Not phased

   Ages

   22 to 65

   Site

   The University of Texas Health Science Center, Houston, Houston, Texas

   Run by

   The University of Texas Health Science Center, Houston

   See if you can join NCT05276050 on ClinicalTrials.gov

2. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

   The purpose of this study is to evaluate the efficacy and safety of KarXT for treatment of Schizophrenia in adolescents.

   Stage

   Phase 3

   Ages

   13 to 17

   Site

   Local Institution - 0120, Houston, Texas

   Locations

   38 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07288567 on ClinicalTrials.gov

3. Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

   This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.

   Stage

   Phase 3

   Ages

   5 to 17

   Site

   Kaleidoscope Clinical Research, Houston, Texas

   Locations

   64 in total

   Run by

   Intra-Cellular Therapies, Inc.

   See if you can join NCT06229210 on ClinicalTrials.gov

4. A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively

   The purpose of this study is to evaluate the long-term safety and tolerability of KarXT and KarX-EC for the treatment of Schizophrenia and autism-related irritability in adolescents, respectively

   Stage

   Phase 3

   Ages

   5 to 17

   Site

   Local Institution - 0169, Houston, Texas

   Locations

   91 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT07424404 on ClinicalTrials.gov

5. Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

   The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United States

   Stage

   Not phased

   Ages

   18 and older

   Site

   Pioneer Research Solutions, Inc., Houston, Texas

   Locations

   55 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07379827 on ClinicalTrials.gov

6. A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

   Evaluate the efficacy and safety of Ulotaront (SEP-363856) in acutely psychotic subjects with schizophrenia

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   HD Research - Memorial Hermann Surgery Center Memorial Village, Houston, Texas

   Locations

   73 in total

   Run by

   Otsuka Pharmaceutical Development & Commercialization, Inc.

   See if you can join NCT06894212 on ClinicalTrials.gov

7. Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)

   Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from H coil for improving white matter integrity.

   Stage

   Not phased

   Ages

   18 to 60

   Site

   The University of Texas Health Science Center, Houston, Houston, Texas

   Run by

   The University of Texas Health Science Center, Houston

   See if you can join NCT06345963 on ClinicalTrials.gov

8. Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 2)

   Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from H coil combined with cognitive training for improving white matter integrity.

   Stage

   Not phased

   Ages

   18 to 60

   Site

   The University of Texas Health Science Center, Houston, Houston, Texas

   Run by

   The University of Texas Health Science Center, Houston

   See if you can join NCT06961916 on ClinicalTrials.gov

9. NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

   This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Neurocrine Clinical Site, Houston, Texas

   Locations

   57 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT07114874 on ClinicalTrials.gov

10. Ocrelizumab for Psychosis by Autoimmunity

    Some people who have what doctors currently call schizophrenia or bipolar disease may actually have a brain disease caused by auto-antibodies. Auto-antibodies are produced when the normal defense mechanism of the body goes wrong and begins to attack the body, similar to "friendly fire." Auto-antibo…

    Stage

    Phase 1

    Ages

    18 to 35

    Site

    Houston Methodist Research Institute, Houston, Texas

    Run by

    The Methodist Hospital Research Institute

    See if you can join NCT03971487 on ClinicalTrials.gov

11. NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

    The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Neurocrine Clinical Site, Houston, Texas

    Locations

    21 in total

    Run by

    Neurocrine Biosciences

    See if you can join NCT06963034 on ClinicalTrials.gov

12. Randomized Withdrawal Study in Patients With Schizophrenia

    The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Vanda Investigational Site, Houston, Texas

    Locations

    22 in total

    Run by

    Vanda Pharmaceuticals

    See if you can join NCT06961968 on ClinicalTrials.gov